Dr. Tombal on Darolutamide Monotherapy in Newly Diagnosed mHSPC

Bertrand Tombal, MD, PhD, discusses the rationale for conducting a phase 2 study of darolutamide monotherapy in newly diagnosed metastatic hormone-sensitive prostate cancer.

Bertrand Tombal, MD, PhD, professor of physiology, chair of the Division of Urology, the Université catholique de Louvain, the Cliniques universitaires Saint-Luc, in Brussels, Belgium, discusses the rationale for conducting a phase 2 study (NCT02972060) of darolutamide (Nubeqa) monotherapy in newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).

The open-label EORTC-GUCG 1532 study was designed to investigate the efficacy of darolutamide, as well as the treatment’s ability to achieve prostate-specific antigen (PSA) suppression and lower testosterone in the absence of androgen-deprivation therapy (ADT) for patients with hormone-naïve, histologically confirmed prostate cancer. Patients across all stages were enrolled in the trial and were required to have a maximum of 4 metastatic lesions, be eligible for hormonal treatment, have an ECOG performance status of 0, and a life expectancy greater than 1 year, Tombal says. The primary end point of the trial was the proportion of patients achieving PSA response at 6 months relative to baseline. Moreover, PSA response was defined as PSA decline greater than 80%, Tombal explains.

Results showed that darolutamide monotherapy was associated with a significant PSA response in this patient population, Tombal continues. At week 24, the PSA response rate was 100% in the monotherapy arm, with a median range decrease of 99.6%. Moreover, this response was comparable with responses with darolutamide plus ADT, Tombal details. Serum testosterone levels in the darolutamide monotherapy arm also increased by a median range of 43.4%. In terms of safety data, 45.2% of patients reported primarily grade 1/2 treatment-related adverse events (TRAEs).

Additional quality-of-life (QoL) data was assessed using the standard EORTC QLQ-PR25 questionnaire, as well as the Aging Male Symptoms scale for male hypergonadism, Tombal adds. Darolutamide alone elicited a lower mean change score according to the EORTC and a lower AMS questionnaire score. This indicates that the regimen elicits lesser less severe hypogonadism-related AEs, respectively. 

Editor’s Note: Dr. Tombal reports serving as a consultant or in an advisory role for Astellas Pharma, Bayer, Ferring, Janssen, Myovant Sciences, Pfizer, Sanofi, Steba Biotech, Takeda; he reports institutional research funding from Ferring; he has served on the Speakers' Bureau for Amgen, Astellas Pharma, Janssen; he received honoraria from Amgen, Astellas Pharma, Bayer, Ferring, Janssen, Myovant Sciences, Pfizer, Sanofi.

Related Videos
Linda Fleisher, PhD, MPH
David Gerber, MD
Shanita Hughes-Halbert, PhD
Brian Mitzman, MD, FACS, FCCP
Matthew Brunner, MD, assistant professor, hematologic specialist, medical oncology, and palliative care, Department of Medicine, University of Wisconsin Carbone Cancer Center
Akash Mukherjee, MD
Jubilee Brown, MD, professor, director, gynecologic oncology, Levine Cancer Institute, Atrium Health
Jean Wright, MD
Steven Cai, MD, FACS
Hyman B. Muss, MD
Related Content